The Adenosine Receptor A2b pipeline drugs market research report outlays comprehensive information on the Adenosine Receptor A2b targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Adenosine Receptor A2b pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Infectious Disease, and Cardiovascular which include the indications Solid Tumor, Colorectal Cancer, Asthma, Pulmonary Fibrosis, Sepsis, Clostridioides difficile Infections (Clostridium difficile Associated Disease), Myocardial Infarction, and Atherosclerosis. It also reviews key players involved in Adenosine Receptor A2b targeted therapeutics development with respective active and dormant or discontinued products.
The Adenosine Receptor A2b pipeline targets constitutes close to 23 molecules. Out of which, approximately 22 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 1, 1, 8, and 8 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Adenosine Receptor A2b overview
The adenosine A2B receptor, also known as ADORA2B, is a G-protein coupled adenosine receptor. It consists of a single polypeptide chain that spans the membrane seven times. The amino terminal is extracellular and the carboxy terminal is intracellular. The adenosine A2B receptor is expressed by and regulates two major energy-dissipating tissues, skeletal muscle and brown fat.
For a complete picture of Adenosine Receptor A2b’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
